Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia.
The effectivity of Sabal serrulata extract in the treatment of symptomatic prostatic hyperplasia was scrutinized in 38 patients. In the course of the 12-month treatment followed up by examinations, the subjective complaints abated in almost 3/4 of the cases. Adverse effects were not encountered. According to uroflowmetry, the average peak flow rate increased from 10.36 ml/s to 14.44 ml/s (p < 0.0001), while the average middle stream increased from 6.02 ml/s to 7.45 ml/s (p < 0.001). Urinary retention decreased or disappeared in more than 9/10 of the cases. The average amount of the residue decreased by 47 ml (p < 0.001). The average volume of the prostate was reduced by 10.6% (p < 0.02). On the basis of the favourable results, Sabal serrulata extract is recommended in the treatment of prostatic hyperplasia producing symptoms of mild and moderate severity.
Kondás
J
J
Department of Urological Surgery, Municipal Péterfy Sándor Street Hospital, Budapest, Hungary.
Philipp
V
V
Diószeghy
G
G
D000368:Aged; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005227:Fatty Acids / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009929:Organ Size / Q000187:drug effects; D010840:Phytosterols / Q000627:therapeutic use*; D010936:Plant Extracts / Q000627:therapeutic use; D011467:Prostate / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000188:drug therapy*; D012720:Severity of Illness Index; D014563:Urodynamics / Q000187:drug effects*
D004791:Enzyme Inhibitors; D005227:Fatty Acids; C099102:IDS 89 Sabal serrulata extract; D010840:Phytosterols; D010936:Plant Extracts